Johnson & Johnson's Janssen division has claimed a first approval in the US for its bispecific antibody Rybrevant as a treatment for EGFR-mutated non-small cell lung cancer (NSCLC).

The standard option for many patients with non-small cell lung cancer today is AstraZeneca’s targeted therapy Tagrisso. A year and a half ago, data showed this drug could provide patients with ...

A better understanding of early childhood microbiome shifts offers a unique window for detecting disease risk and intervening appropriately. Experts from the Women’s Brain Foundation and bit.bio will ...

Six deaths reported this past week in McLeod County were attributed to COVID-19, according to data from the Minnesota Department of Health. It was the deadliest week of the pandemic since last ...

Johnson & Johnson’s Janssen unit has filed for approval of its multiple myeloma CAR-T ciltacabtagene autoleucel in Europe, chasing after a rival therapy from Bristol-Myers Squibb.

EMA committee recommends extension of marketing authorisation for Janssen-Cilag’s subcutaneous Rybrevant to treat advanced EGFR-mutated NSCLC: Beerse, Belgium Tuesday, February ...

Janssen looks for partnerships where the sum is greater than the parts—a synergistic focus that benefits both parties. As part of Johnson & Johnson, Janssen can leverage an array of resources to ...

Halozyme (HALO) announced that Janssen-Cilag International, a Johnson & Johnson (JNJ) company, received a positive opinion from the ...

Janssen-Cilag International NV, a Johnson & Johnson company, received European Medicines Agency's Committee for Medicinal Products ...